Personalis, Inc. Launches NeXT Liquid Biopsy™, A High-Performance, Exome-Wide Liquid Biopsy Platform
03 8월 2020 - 9:17PM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for cancer, today announced the launch of NeXT Liquid Biopsy, a
high-performance, exome-scale, tumor-profiling platform that
utilizes blood samples from advanced-stage solid tumor cancer
patients. NeXT Liquid Biopsy, paired with Personalis’ leading
ImmunoID NeXT™ tissue profiling platform, enables a more
comprehensive immuno-genomics view of the tumor that can now be
monitored over time from blood samples. NeXT Liquid Biopsy monitors
over twenty times more genes than the majority of liquid biopsy
cancer panels on the market today. These capabilities will help
biopharmaceutical companies advance their understanding of tumor
biology, including resistance mechanisms, to aid the development of
next-generation cancer therapies.
Personalis CEO, John West, said, “Solid tumor biopsies and
liquid biopsies complement each other, and it is important to
utilize both in cancer research. Solid tumor biopsies can yield
information about mutations, gene expression, the tumor
microenvironment, and immune cells that have infiltrated the tumor,
while liquid biopsies can track mutations and detect new mutations
over time in response to treatment. By combining NeXT Liquid Biopsy
with ImmunoID NeXT, researchers now have a powerful tool to address
tumor heterogeneity, longitudinally monitor clonal and subclonal
dynamics, identify acquired resistance mechanisms, and access key
areas of tumor biology not typically included in targeted liquid
biopsy panels. We strongly believe this will provide a powerful
framework for translational research, and the development of
next-generation cancer therapeutics to overcome therapy resistance
and cancer progression.”
Mr. West added, “Through our collaborations program, we are
encouraged by our partners’ response to NeXT Liquid Biopsy. NeXT
Liquid Biopsy represents a new capability in the market and we look
forward to working closely with our first customers. This is just
the first step in Personalis’ liquid biopsy product portfolio and
we are excited for further developments in this area.”
NeXT Liquid Biopsy is immediately available for order.
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company
transforming the development of next-generation therapies by
providing more comprehensive molecular data about each patient’s
cancer and immune response. The Personalis® ImmunoID NeXT Platform®
is designed to adapt to the complex and evolving understanding of
cancer, providing its biopharmaceutical customers with information
on all of the approximately 20,000 human genes, together with the
immune system, from a single tissue sample. Personalis also
provides genomic information to the VA Million Veterans Program as
part of their goal to sequence over a million veteran genomes. The
Personalis Clinical Laboratory is GxP aligned as well as
CLIA’88-certified and CAP-accredited. For more information, please
visit www.personalis.com and follow Personalis on Twitter
(@PersonalisInc).
Forward-Looking Statements
This press release contains or may imply "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements include all statements that are not
historical facts, including, for example, statements relating to
the capabilities, availability or benefits of NeXT Liquid Biopsy,
potential advancement of or growth opportunities for Personalis’
business, expansion of Personalis’ market presence in
immuno-oncology, the company’s services for the VA Million Veterans
Program, and other future events. These forward-looking statements
are subject to risks and uncertainties, including those related to
the evolution of cancer therapies and market adoption of our
services, our expectations regarding future performance, and the
COVID-19 pandemic, as well as other risks and uncertainties
discussed in Personalis’ filings with the Securities and Exchange
Commission (SEC), including in the “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of
Operations” sections of the Company’s most recently filed periodic
reports on Forms 10-K and 10-Q and subsequent filings and in the
documents incorporated by reference therein, all of which may
significantly impact our business and operations, the business and
operations of our customers, our ability to access capital and the
value of our common stock. Except as otherwise required by law,
Personalis disclaims any intention or obligation to update or
revise any forward-looking statements, which speak only as of the
date hereof, whether as a result of new information, future events
or circumstances or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200803005252/en/
Contacts for Personalis,
Inc. Investor Relations Contact for Personalis:
Caroline Corner investors@personalis.com 415-202-5678
Media Contact for Personalis: Jennifer Havlek
pr@personalis.com www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024